Quarterly report pursuant to Section 13 or 15(d)

Long-Term Debt and Other Financings - Novartis Note (Details)

v3.20.2
Long-Term Debt and Other Financings - Novartis Note (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Oct. 21, 2020
May 31, 2005
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2017
Dec. 31, 2015
Dec. 31, 2019
Sep. 30, 2015
Long-term debt                    
Debt amount     $ 29,952   $ 29,952          
Revenue from contracts with customers     $ 200 $ 8,525 $ 753 $ 17,176        
Novartis Note                    
Long-term debt                    
Research and development expenses funded through loan facility, maximum (as a percent)   75.00%                
Maximum borrowing capacity under loan agreement   $ 50,000                
Interest rate at period end (as a percent)     2.41%   2.41%          
Amount by which note will be reduced upon achievement of specified milestones                   $ 7,300
Debt amount     $ 16,200   $ 16,200       $ 15,900  
Novartis Note | Six-month LIBOR                    
Long-term debt                    
Basis spread on variable rate   2.00%                
Subsequent Event | Novartis Note                    
Long-term debt                    
Reduction in debt obligation $ 7,300                  
Novartis International | License Agreement                    
Long-term debt                    
Revenue from contracts with customers     $ 0 $ 0 $ 0 $ 0 $ 10,000 $ 37,000    
Novartis International | License Agreement | Subsequent Event                    
Long-term debt                    
Revenue from contracts with customers $ 25,000